lisdexamfetamine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 42 Diseases   12 Trials   12 Trials   1286 News 


«12345678910111213...1415»
  • ||||||||||  methylphenidate tablet / Generic mfg., risperidone / Generic mfg., lorazepam / Generic mfg.
    Biomarker, Clinical, Journal:  Psychotropic prescribing rates and pharmacogenomic testing implications for autism in the Canadian primary care sentinel surveillance network. (Pubmed Central) -  Apr 2, 2022   
    In this long-term 52-week study of children aged 4-5 years with ADHD, dose-optimized LDX (5-30 mg) was well tolerated and associated with reductions from baseline in ADHD symptoms. Our findings suggest primary care providers in Canada prescribe a wide range of psychotropics to their patients with autism, some of which may benefit from the integration of pharmacogenomic information into their treatment planning.
  • ||||||||||  methylphenidate tablet / Generic mfg., amphetamine / Generic mfg.
    Review, Journal:  The potential role of stimulants in treating eating disorders. (Pubmed Central) -  Apr 2, 2022   
    Our findings suggest primary care providers in Canada prescribe a wide range of psychotropics to their patients with autism, some of which may benefit from the integration of pharmacogenomic information into their treatment planning. Although this line of investigation may be viewed as controversial by some in the field, we believe that the topic warrants careful consideration for future research.
  • ||||||||||  methylphenidate tablet / Generic mfg., atomoxetine / Generic mfg.
    Journal:  Trend in medicines use for attention deficit hyperactivity disorder in children and adolescents (2010-2019). (Pubmed Central) -  Mar 30, 2022   
    Although this line of investigation may be viewed as controversial by some in the field, we believe that the topic warrants careful consideration for future research. Approximately 2 out of every 100 people aged 0-19 years were treated with some ADHD medication, mainly methylphenidate, in Castilla y León between 2010 and 2019.
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Trial completion date, Trial primary completion date:  Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism (clinicaltrials.gov) -  Mar 29, 2022   
    P4,  N=40, Recruiting, 
    Approximately 2 out of every 100 people aged 0-19 years were treated with some ADHD medication, mainly methylphenidate, in Castilla y León between 2010 and 2019. Trial completion date: Oct 2021 --> Dec 2022 | Trial primary completion date: Oct 2021 --> Dec 2022
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda
    Journal:  Lisdexamfetamine-Associated Tonsure Trichotillomania. (Pubmed Central) -  Mar 5, 2022   
    Further research and head-to-head studies should be considered to strengthen the best available options for TRD. No abstract available
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda
    Journal:  Use of Lisdexamfetamine or Amphetamine? Interpretation of Chiral Amphetamine Analyses. (Pubmed Central) -  Feb 16, 2022   
    Furthermore, no formation of l-amphetamine occurred during storage for three months at 4°C, nine months at -20°C and three freeze-thaw cycles. The results from this study may be helpful in the interpretation of whether the source of identified amphetamine in biological samples are from LDX drug intake or not.
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda
    Journal:  Hypoglycemia and presumptive rhabdomyolysis secondary to lisdexamfetamine toxicosis in 3 cats. (Pubmed Central) -  Feb 2, 2022   
    This is the first case series in cats that reports the novel biochemical changes of delayed hypoglycemia and elevated creatine kinase several days into hospitalization for the treatment of LDX toxicity. The development of delayed clinical signs suggests reconsideration of established hospitalization guidelines for amphetamine ingestion in cats.
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda
    LISDEXAMFETAMINE RELATED VENTRICULAR TACHYCARDIA (Poster Hall_Hall C) -  Jan 28, 2022 - Abstract #ACC2022ACC_2392;    
    He was then given a 150mg bolus of IV amiodarone and started on an infusion, with IV fluid hydration. Tachycardia is a known side effect of lisdexamphetamine used for ADHD however, VT is a very rare but potentially fatal adverse effect in these patients, whose youth may lead to delays in care or missed diagnosis.
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda
    LISDEXAMFETAMINE INDUCED VASOSPASM LEADING TO CARDIAC CATHETERIZATION IN A 34-YEAR-OLD FEMALE (Poster Hall_Hall C) -  Jan 28, 2022 - Abstract #ACC2022ACC_1157;    
    Identified triggers include drugs such as ephedrine, sumatriptan, and recreational drugs like cocaine, amphetamines, alcohol, and marijuana. Although acute coronary syndrome likely secondary to prescribed amphetamine in the absence of any other known risk factors is a rare occurrence, there should be a high degree of suspicion for VA even in the absence of ST- changes on EKG.
  • ||||||||||  Vyvanse (lisdexamfetamine) / Shionogi, Takeda
    Imaging The Treatment Of Adhd () -  Dec 18, 2021 - Abstract #AACAP2021AACAP_1153;    
    In this work, we aim to identify causal effects of psychostimulants on brain connectivity in individuals with ADHD and their relationship with symptom improvement.Methods In a 12-week, randomized, placebo-controlled trial of lisdexamfetamine (LDEX), 49 out of 58 eligible participants (12.6 [5.7] years; 33 [67%] males; 25 LDEX and 24 placebo) completed both pre– and post–randomized controlled trial MRI scanning with adequate data quality...Independent samples yielded similar findings: ADHD was associated with increased dynamic FC, and psychostimulants with reduced dynamic FC.Conclusions We found that changes in dynamic, not static, FC accounted for therapeutic effects of psychostimulants. Altered dynamic FC may represent a reliable target for new ADHD interventions aimed at stabilizing network dynamics.ADHD, RCT, STIM
  • ||||||||||  dextroamphetamine modified release (HLD-100) / Highland Therapeutics
    Higher Persistence And Adherence With Dr/Er-Mph Over Other Extended-Release Stimulants For The Management Of Adhd: Real-World Evidence From A Large U.S. Claims Database Analysis () -  Dec 18, 2021 - Abstract #AACAP2021AACAP_1076;    
    Adherence was also highest with DR/ER-MPH at 92%, compared to 89% for LDX, 89% for generic ER AMP, 88% for branded analogs, and 88% for generic MPH (p < 0.01 for all).Conclusions Although not adjusted for comorbidities or other baseline characteristics, individuals showed higher persistence and adherence over 9 months with DR/ER-MPH compared to other ER stimulants, which may be a result of its unique evening administration and/or dose-dependent duration effect. Higher persistence and adherence are predicted to translate into improved outcomes for ADHD patients.
  • ||||||||||  NN1213 / Novo Nordisk, Intuniv (guanfacine XR) / Shionogi, Takeda
    Trial completion, Enrollment change, Trial completion date:  An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD (clinicaltrials.gov) -  Dec 14, 2021   
    P=N/A,  N=38, Completed, 
    Higher persistence and adherence are predicted to translate into improved outcomes for ADHD patients. Active, not recruiting --> Completed | N=160 --> 38 | Trial completion date: Sep 2022 --> Nov 2021
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Enrollment closed:  IMPRES: IMProving Executive Function Study (clinicaltrials.gov) -  Dec 6, 2021   
    P4,  N=100, Active, not recruiting, 
    To advance reproducible open science, our report is accompanied with links providing access to our data and analytic scripts. Recruiting --> Active, not recruiting
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Trial completion:  Drug Use Study With VYVANSE (clinicaltrials.gov) -  Nov 22, 2021   
    P=N/A,  N=150, Completed, 
    Altogether, these computational techniques are proven an excellent tool for hypothesis-generation and would help reach a personalized medicine. Active, not recruiting --> Completed
  • ||||||||||  Review, Journal:  Pharmacological treatment of eating disorders, comorbid mental health problems, malnutrition and physical health consequences. (Pubmed Central) -  Nov 17, 2021   
    Acute anxiety or suicidality may warrant benzodiazepine treatment with lorazepam...Therapeutic drug monitoring, pharmacogenomic testing, a more restrictive use of "pro re nata" (PRN) medication, an interdisciplinary treatment approach, shared decision making (SDM) and the formulation of common treatment goals by the patients, their family or carers and clinicians could improve treatment success and safety. Novel genetic, immunological, microbiome and brain imaging research as well as new pharmacological developments like the use of psychedelics, stimulants, novel monoaminergic drugs, hormone analogues and drugs which enhance the effects of psychotherapy may extend our therapeutic options in the near future.
  • ||||||||||  lisdexamfetamine / Generic mfg.
    Enrollment change:  Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT (clinicaltrials.gov) -  Nov 16, 2021   
    P2,  N=38, Completed, 
    Further research is warranted to exclude the risk of sympathomimetic toxidrome if intact LDX capsules simultaneously disintegrate in the gastrointestinal tract. N=86 --> 38